Antiemetics And Antinauseants Market Growth Trajectory Through 2024-2033|Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG,

The Antiemetics And Antinauseants Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Antiemetics And Antinauseants Market:
https://www.thebusinessresearchcompany.com/report/antiemetics-and-antinauseants-global-market-report

According to The Business Research Company’s Antiemetics And Antinauseants Global Market Report 2024, The antiemetics and antinauseants market size has grown steadily in recent years. It will grow from $7.75 billion in 2023 to $8.09 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to historical branding and market competition, historical treatment preferences, economic conditions, historical global health events, medical advancements and research.

The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to research and development initiatives, economic factors, market competition and industry trends, changing disease patterns, healthcare policies and regulations. Major trends in the forecast period include increased focus on patient experience, changing healthcare policies, consumer preference for non-invasive treatments, rising prevalence of chemotherapy and pregnancy-related nausea, emergence of targeted therapies.

The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2441&type=smp

The antiemetics and antinauseants market covered in this report is segmented –

1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types
2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types
3) By End Users: Hospital, Medical Center, Clinic, Research Institutes

Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently.

The antiemetics and antinauseants market report table of contents includes: